Hims & Hers Health, Inc. (HIMS) Stock Price & Analysis

Hims & Hers Health, Inc. (HIMS) fell 0.40% to USD 27.71 as of September 8, 2026 at 04:21 UTC, according to Nexqual real-time market data.

HIMS last closed at USD 27.71; the session ranged USD 27.38–27.95 on volume of 6,598,863 shares. Market capitalization is —, with a 52-week range of USD 13.74–65.3 (NYQ). Source: Nexqual, September 8, 2026 at 04:21 UTC.

Key Statistics (as of September 8, 2026 at 04:21 UTC)

Technical Analysis (HIMS)

Nexqual's technical model rates HIMS "SELL" based on 1 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 04:21 UTC.

From Hims & Hers Health, Inc.'s Latest SEC 10-K Filing (filed 2026-02-23)

Key Strengths & Strategy (as disclosed to the SEC)

• Healthcare providers, including Providers prescribing on our platform, are permitted to prescribe drugs offered on the platform for "off-label" uses (i.e., uses not approved by the FDA and not described in the product's labeling) because the FDA generally does not regulate the practice of medicine.
• We have relationships with leading health systems in the U.S. including, as of December 31, 2025, Ochsner Health, Mount Sinai Health System, Carbon Health, ChristianaCare Health System, and Hartford Healthcare to provide a clinically focused, telehealth-enabled patient care collaboration.
• Regulatory and/or legal enforcement actions by the Food and Drug Administration (the "FDA"), Department of Health and Human Services, or other international, federal, state, or foreign enforcement authorities could have material adverse consequences on our business or its operations.
• Once we have commenced commercial operations, these operations will be subject to provisions governing FDA-registered manufacturers of active pharmaceutical ingredients ("API"), as well as federal regulations regarding cGMP applicable to API manufacturers.

Partnerships

• Several cosmetics and supplement products have been developed by us in partnership with the applicable manufacturers.
• Organic growth is enhanced by sophisticated omnichannel acquisition strategies meant to target future customers with condition-specific on-ramps at profitable returns on investment.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 04:21 UTC. This page is informational and not investment advice.